A small molecule induces readthrough of cystic fibrosis CFTR nonsense mutations
(University of Alabama at Birmingham) An experimental drug reported in Nature Communications suggests that a " path is clearly achievable " to treat currently untreatable cases of cystic fibrosis disease caused by nonsense mutations. This includes about 11 percent of cystic fibrosis patients, as well as patients with other genetic diseases, including Duchenne muscular dystrophy,β-thalassemia and numerous types of cancers, that are also caused by nonsense mutations. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 19, 2021 Category: International Medicine & Public Health Source Type: news

Should the most vulnerable be shielding again - no matter what health chiefs say?
The Cystic Fibrosis Trust, Blood Cancer UK and Kidney Care UK, among others, have called for specific guidance for the most vulnerable after tomorrow's so-called Freedom Day. (Source: the Mail online | Health)
Source: the Mail online | Health - July 17, 2021 Category: Consumer Health News Source Type: news

Ex-Genentech principal scientist, husband plead guilty in trade secrets case; two others charged
The case centers on three blockbuster cancer drugs developed by Genentech as well as a cystic fibrosis treatment and spans the globe. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 8, 2021 Category: American Health Authors: Ron Leuty Source Type: news

A Disposable OPEP Device in Children With Cystic Fibrosis A Disposable OPEP Device in Children With Cystic Fibrosis
A novel daily disposable OPEP device may be as effective as reusable devices while eliminating the need for regular cleaning.BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 6, 2021 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Cystic Fibrosis: Overjoyed family opens up about transformed life with wonder drug
AN overjoyed family poses with their new arrival a year after their lives were changed by a cystic fibrosis drug fought for by the Daily Express. (Source: Daily Express - Health)
Source: Daily Express - Health - July 5, 2021 Category: Consumer Health News Source Type: news

Whole genome sequencing of all UK newborns ‘would have public support’
Consultation shows positivity towards screening programme to spot those at heightened risk of certain health conditionsPlans to sequence the whole genome of every newborn in the UK in order to spot those at heightened risk of certain health conditions have been given a boost, with consultations suggesting the approach could have public support.The potential for genomics to improve health was at theheart of the chief medical officer annual report of 2016, with a group of experts convened by Genomics England – a government-owned genetics service – subsequently recommending a research programme to sequence the who...
Source: Guardian Unlimited Science - July 4, 2021 Category: Science Authors: Nicola Davis Science correspondent Tags: Genetics Science UK news NHS Health Childbirth Sickle cell disease Cystic fibrosis Children's health Source Type: news

Diversity is a Living Thing
p{ margin:10px 0; padding:0; } table{ border-collapse:collapse; } h1,h2,h3,h4,h5,h6{ display:block; margin:0; padding:0; } img,a img{ border:0; height:auto; outline:none; text-decoration:none; } body,#bodyTable,#bodyCell{ height:100%; margin:0; padding:0; width:100%; } .mcnPreviewText{ display:none !important; } #outlook a{ padding:0; } img{ -ms-interpolation-mode:bicubic; } table{ mso-table-lspace:0pt; mso-table-rspace:0pt; } .ReadMsgBody{ width:100%; } .ExternalClass{ width:100%; } p,a,li,td,blockquote{ m...
Source: Johns Hopkins University and Health Systems Archive - June 29, 2021 Category: Nursing Source Type: news

What Types of New Therapies are Available for Cystic Fibrosis?
Discussion Cystic fibrosis (CF) was identified in 1938 by Dr. Dorothy Andersen who described 49 patients with pancreatic insufficiency. Since that time significant achievements in the knowledge about the disease and treatments for patients have changed the mortality from a few months to patients living into middle adulthood or even later. Quality of life for patients and their families and friends has also markedly improved. CF is the classic Mendelian autosomal recessive genetic disorder which is a worldwide disorder but affects people of north European ancestry more often where the main mutation is more common. There are...
Source: PediatricEducation.org - June 28, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
BOSTON--(BUSINESS WIRE)--Jun. 9, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved expanded use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 9, 2021 Category: Drugs & Pharmacology Source Type: news

How strengthening the biosimilar marketplace benefits patients
Biologics are medicines that are made from living organisms through highly complex manufacturing processes and include a wide variety of medicines such as therapeutic proteins, monoclonal antibodies and vaccines. They are used to prevent or treat a variety of diseases including cancer, chronic kidney disease, diabetes, cystic fibrosis and autoimmune disorders.  (Source: The Catalyst)
Source: The Catalyst - May 18, 2021 Category: Pharmaceuticals Tags: FDA Drug Cost Biologics and Biosimilars Source Type: news

Health outcomes differ between UK and US children with cystic fibrosis
(University of Liverpool) A new study led by University of Liverpool researchers has confirmed that children with cystic fibrosis (CF) in the US have better lung function than UK children with the disease. The study suggests that differences do not appear to be explained by early growth or nutrition, but could be linked to differences in the use of early treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 14, 2021 Category: International Medicine & Public Health Source Type: news

SpliSense Secures $28.5 Million in Series B Financing
Round includes up to $8.4 million investment by the Cystic Fibrosis Foundation Funds will be used to advance the Company's mRNA-altering pipeline for the treatment of cystic fibrosis and other genetic pulmonary diseases JERUSALEM, May 13, 2021 -- (He... Biopharmaceuticals, Venture Capital SpliSense, Cystic Fibrosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 13, 2021 Category: Pharmaceuticals Source Type: news

Antimicrobial prescribing: nebulised liposomal amikacin - evidence summary [ES36], NICE (published 12th May 2021)
This concludes nebulised liposomal amikacin may be an option for treating non-tuberculous mycobacterial lung infections caused by Mycobacterium avium complex in combination with other antimicrobial agents in adults with limited treatment options& who do not have cystic fibrosis. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 13, 2021 Category: Consumer Health News Source Type: news

Novel nanotech improves cystic fibrosis antibiotic by 100,000-fold
(University of South Australia) World-first nanotechnology developed by the University of South Australia could change the lives of thousands of people living with cystic fibrosis (CF) as groundbreaking research shows it can improve the effectiveness of the CF antibiotic Tobramycin, increasing its efficacy by up to 100,000-fold. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 13, 2021 Category: Biology Source Type: news

New study determines cystic fibrosis therapy is safe and effective for young children
(Children's Hospital Colorado) Children ages two to five who have the most common form of cystic fibrosis have not had any modulator treatments available to them until recently. A new study authored by researchers at Children's Hospital Colorado and published May 6, 2021, in Lancet Respiratory Medicine shows that the CFTR modulator - lumacaftor/ivacaftor - can be safe and well-tolerated for this age range for up to 120 weeks, allowing younger children to begin proactive treatment of CF. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 7, 2021 Category: International Medicine & Public Health Source Type: news

Molecular analysis identifies key differences in lungs of cystic fibrosis patients
A team of researchers from UCLA, Cedars-Sinai and the Cystic FibrosisFoundation has developed a first-of-its-kind molecular catalog of cells in healthy lungs and the lungs of people with cystic fibrosis.The catalog,described today in the journal Nature Medicine, reveals new subtypes of cells and illustrates how the disease changes the cellular makeup of the airways. The findings could help scientists in their search for specific cell types that represent prime targets for genetic and cell therapies for cystic fibrosis.“This new research has provided us with valuable insights into the cellular makeup of both heal...
Source: UCLA Newsroom: Health Sciences - May 7, 2021 Category: Universities & Medical Training Source Type: news

Molecular analysis identifies key differences in lungs of cystic fibrosis patients
(Cedars-Sinai Medical Center) A team of researchers from UCLA, Cedars-Sinai and the Cystic Fibrosis Foundation has developed a first-of-its-kind molecular catalog of cells in healthy lungs and the lungs of people with cystic fibrosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 6, 2021 Category: International Medicine & Public Health Source Type: news

Multi-drug resistant infection about to evolve within cystic fibrosis patients
(University of Cambridge) Scientists have been able to track how a multi-drug resistant organism is able to evolve and spread widely among cystic fibrosis patients - showing that it can evolve rapidly within an individual during chronic infection. The researchers say their findings highlight the need to treat patients with Mycobacterium abscessus infection immediately, counter to current medical practice. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 29, 2021 Category: Infectious Diseases Source Type: news

Bypassing broken genes
(Penn State) A new approach to gene editing using the CRISPR/Cas9 system bypasses disease-causing mutations in a gene, enabling treatment of genetic diseases linked to a single gene, such as cystic fibrosis, certain types of sickle cell anemia, and other rare diseases. The method involves inserting a new, fully functional copy of the gene that displaces the mutated gene. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 21, 2021 Category: International Medicine & Public Health Source Type: news

Study aims to improve health of patients with CF across their increasing lifespan
(Medical College of Georgia at Augusta University) People with cystic fibrosis are living better and longer, and now investigators want to further enhance quality and longevity by better understanding the role of nutrition, body composition and exercise in their health across an increasing lifespan. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 19, 2021 Category: International Medicine & Public Health Source Type: news

Three - Drug Regimen Treats Cystic Fibrosis in Younger Children
Elexacaftor/tezacaftor/ivacaftor well tolerated in children aged 6 through 11 years with cystic fibrosis and at least one F508del - CFTR allele (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 14, 2021 Category: Respiratory Medicine Tags: Family Medicine, Pediatrics, Pharmacy, Pulmonology, Journal, Source Type: news

Three-Drug Regimen Treats Cystic Fibrosis in Younger Children
WEDNESDAY, April 14, 2021 -- The safety and efficacy of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) for the treatment of cystic fibrosis with at least one F508del-CFTR allele in children aged 6 to 11 years are consistent with the results reported... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 14, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Investor Update - April 13, 2021 Category: Pharmaceuticals Source Type: news

< a href= " /news-events/nih-research-matters/sweat-sticker-diagnosing-cystic-fibrosis " > “Sweat sticker” for diagnosing cystic fibrosis < /a >
Researchers created a “sweat sticker” for measuring chloride concentrations in sweat, a sign of cystic fibrosis. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - April 13, 2021 Category: Consumer Health News Source Type: news

Bioengineer wins NIH grant to attack cystic fibrosis
(Rice University) Rice University chemical and biomolecular engineer Xue Sherry Gao wins a prestigious National Institutes of Health R01 grant to develop personalized gene editing techniques for cystic fibrosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 8, 2021 Category: International Medicine & Public Health Source Type: news

Cystic Fibrosis: More patients can have wonder drug - hope for hundreds
A WONDER drug that "almost cures" cystic fibrosis can be given to hundreds more English patients. (Source: Daily Express - Health)
Source: Daily Express - Health - April 5, 2021 Category: Consumer Health News Source Type: news

Can a'Sweat Sticker' Improve Diagnosis of Cystic Fibrosis? Can a'Sweat Sticker' Improve Diagnosis of Cystic Fibrosis?
The technology may help clinicians monitor how patients respond to treatment and allow for sweat testing outside of clinical settings, researchers suggest.Medscape Medical News (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - April 2, 2021 Category: Pediatrics Tags: Pediatrics News Source Type: news

A simple sweat test for cystic fibrosis
(Source: ScienceNOW)
Source: ScienceNOW - April 1, 2021 Category: Science Authors: Czajka, C. Tags: twis Source Type: news

Soft " sweat stickers " may streamline diagnosis of cystic fibrosis in children
(American Association for the Advancement of Science) New " sweat stickers " may streamline the early diagnosis of cystic fibrosis by enabling scientists to easily gather and analyze sweat from the skin of infants and children. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 31, 2021 Category: International Medicine & Public Health Source Type: news

Dutch medical AI company Thirona launches software for cystic fibrosis
The new algorithm allows for automated analysis of CT scans of patients with the condition. (Source: mobihealthnews)
Source: mobihealthnews - March 31, 2021 Category: Information Technology Tags: AI, Analytics, Predictive analytics, Data and Information Source Type: news

Liesbeth Stoeffler, 61, Runner Kept Going by Rare Lung Treatment, Dies
A machine that acted as an artificial lung kept her eligible for a transplant as she dealt with cystic fibrosis. She went on to compete again in marathons. (Source: NYT Health)
Source: NYT Health - March 26, 2021 Category: Consumer Health News Authors: Richard Sandomir Tags: Cystic Fibrosis Coronavirus (2019-nCoV) Ventilators (Medical) Lungs Running AllianceBernstein Holding LP Austria Manhattan (NYC) Stoeffler, Liesbeth (1959-2021) Transplants Source Type: news

Thirona launches AI algorithm for cystic fibrosis
Software developer Thirona is launching Pragma-AI, a new artificial intelligenc...Read more on AuntMinnie.comRelated Reading: Thirona licenses patent for cystic fibrosis AI software Meet the Minnies 2020 semifinal candidates Thirona, Smart Reporting team up on COVID-19 software Thirona unveils AI software for COVID-19 analysis AI-based CAD accurately detects tuberculosis on chest x-rays (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 25, 2021 Category: Radiology Source Type: news

Therapy for most common cause of cystic fibrosis safe and effective in 6-11
(Ann& Robert H. Lurie Children's Hospital of Chicago) An international, open-label Phase 3 study, co-led by Susanna McColley, MD, from Ann& Robert H. Lurie Children's Hospital of Chicago, found that a regimen of three drugs (elexacaftor/tezacaftor/ivacaftor) that targets the genetic cause of cystic fibrosis was safe and effective in 6-11-year-olds with at least one copy of F508del mutation in the CFTR gene, which is estimated to represent almost 90 percent of the cystic fibrosis population in the United States. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 18, 2021 Category: International Medicine & Public Health Source Type: news

Singapore scientists develop novel gene editor to correct disease-causing mutations
(Agency for Science, Technology and Research (A*STAR), Singapore) The Genome Institute of Singapore (GIS) has developed a CRISPR-based gene editor to correct mutations that cause genetic disorders. The C-to-G Base Editor (CGBE) by GIS advances the widely adopted CRISPR-Cas9 technology to enable molecular surgery on the human genome. This invention opens up treatment options for approximately 40 per cent of single-base substitutions associated with human diseases - including cystic fibrosis, cardiovascular diseases, musculoskeletal diseases, and neurological disorders. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 11, 2021 Category: Biology Source Type: news

Research reveals how bacteria defeat drugs that fight cystic fibrosis
(The University of Montana) University of Montana researchers and their partners have discovered a slimy strategy used by bacteria to defeat antibiotics and other drugs used to combat infections afflicting people with cystic fibrosis. The research was published Feb. 23, 2021 in the journal Cell Reports. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 26, 2021 Category: Infectious Diseases Source Type: news

How do patients with cystic fibrosis respond to COVID-19?
(Boston Children's Hospital) Based on clinical data, patients with cystic fibrosis (CF) don't appear to be especially susceptible to COVID-19, and when they do get infected, they don't seem to get sicker. But Ruobing (Ruby) Wang, MD, a physician-scientist in the Division of Pulmonary Medicine at Boston Children's Hospital, cares for patients with CF and thinks there is more to the story. Thanks to a grant from the Cystic Fibrosis Foundation, Dr. Wang will put her theories to the test. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 22, 2021 Category: International Medicine & Public Health Source Type: news

NIH Director Francis Collins Is Fighting This Coronavirus While Preparing for the Next One
In May 2020, Dr. Francis Collins, the longtime head of the National Institutes of Health (NIH), was called to the White House to meet with Jared Kushner, the then President’s son-in-law and adviser, and Dr. Deborah Birx, the head of the White House Coronavirus Task Force. A few weeks earlier, Congress had given the NIH $1.5 billion to try to speed up the process of developing new diagnostic tests for COVID-19, and the White House, which was dubious about increasing the rate of testing, wanted to know more about what the NIH was doing. Collins is technically the boss of Dr. Anthony Fauci, but during the pandemic he ha...
Source: TIME: Health - February 4, 2021 Category: Consumer Health News Authors: Belinda Luscombe Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Jamie Cary wins major CF award for her work as Certified Child Life Specialist at Upstate ’s Robert C. Schwartz Cystic Fibrosis Center
Cary was one of only two individuals nationwide to receive the Mary M. Kontos Care Champion Award from the Cystic Fibrosis Foundation at the North American Cystic Fibrosis Conference (NACFC) in October 2020. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - February 3, 2021 Category: Universities & Medical Training Tags: News Source Type: news

amie Cary wins major CF award for her work as Certified Child Life Specialist at Upstate ’s Robert C. Schwartz Cystic Fibrosis Center
Cary was one of only two individuals nationwide to receive the Mary M. Kontos Care Champion Award from the Cystic Fibrosis Foundation at the North American Cystic Fibrosis Conference (NACFC) in October 2020. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - February 2, 2021 Category: Universities & Medical Training Tags: News Source Type: news

Updated advice on COVID-19 vaccination in pregnancy and women who are breastfeeding, RCOG
The Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise Oxford University/AstraZeneca's COVID-19 vaccine for use. The Joint Committee on Vaccination and Immunisation (JCVI) has also published its latest advice for the priority groups to receive the Oxford University/AstraZeneca and the Pfizer/BioNTech vaccines. This includes updated advice for pregnant and breastfeeding women who meet other criteria for priority vaccination. The JCVI confirms that although the available data do not indicate any safety concern or harm to pregnancy, there is insuf...
Source: Current Awareness Service for Health (CASH) - December 31, 2020 Category: Consumer Health News Source Type: news

Antifungal drug improves key cystic fibrosis biomarkers in clinical study
(University of Illinois at Urbana-Champaign, News Bureau) A drug widely used to treat fungal infections improved key biomarkers in lung tissue cultures as well as in the noses of patients with cystic fibrosis, a clinical study by researchers at the University of Illinois Urbana-Champaign and the University of Iowa found. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 17, 2020 Category: Biology Source Type: news

Featured Review: Drugs for correcting the basic defect in the most common cystic fibrosis-causing gene variant
Read thisrecently published Cochrane review about CFTR correctors, a therapy for cystic fibrosis targeted at specific variants (most commonly F508del)In this review, the authors looked at drugs (or drug combinations) for correcting the basic defect in the most common cystic fibrosis (CF)-causing gene variant (F508del) and assessed their impact on outcomes important to people with Cystic Fibrosis, e.g. survival, quality of life (QoL), lung function and safety.Professor Kevin Southern, lead author of this review, has been involved in the care of children with CF for over 30 years, and has a deep appreciation of the impact of...
Source: Cochrane News and Events - December 16, 2020 Category: Information Technology Authors: Katie Abbotts Source Type: news

How Is a Person's Life Affected By Cystic Fibrosis?
Title: How Is a Person's Life Affected By Cystic Fibrosis?Category: Diseases and ConditionsCreated: 10/9/2020 12:00:00 AMLast Editorial Review: 12/10/2020 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - December 10, 2020 Category: Respiratory Medicine Source Type: news

Johns Hopkins develops potential antibiotic for drug-resistant pathogen
(Johns Hopkins University) Scientists from Johns Hopkins University and Medicine have developed a possible new antibiotic for a pathogen that is notoriously resistant to medications and frequently lethal for people with cystic fibrosis and other lung ailments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 8, 2020 Category: International Medicine & Public Health Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Media News - December 1, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Investor Update - December 1, 2020 Category: Pharmaceuticals Source Type: news

Telehealth Finds Acceptance Among Patients With Cf, Clinicians Telehealth Finds Acceptance Among Patients With Cf, Clinicians
Telehealth is widely accepted among individuals with cystic fibrosis (CF) and the physicians who treat them, according to three new studies.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 23, 2020 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

COVID-19 rapid guideline: cystic fibrosis, NICE (updated 7th October 2020)
The purpose of this guideline is to maximise the safety of patients with cystic fibrosis and make the best use of NHS resources, while protecting staff from infection.The guideline focuses on what you need to stop or start doing during the pandemic. Follow the usual professional guidelines, standards and laws (including those on equalities, safeguarding, communication and mental capacity), as described in 2 External 0 0 0 making decisions using NICE guidelines false https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-guidelines/making-decisions-using-nice-guidelines true false%>. On 7 October 2020...
Source: Current Awareness Service for Health (CASH) - November 20, 2020 Category: Consumer Health News Source Type: news

Why Is Meconium Ileus Diagnostic for Cystic Fibrosis?
Title: Why Is Meconium Ileus Diagnostic for Cystic Fibrosis?Category: Procedures and TestsCreated: 11/20/2020 12:00:00 AMLast Editorial Review: 11/20/2020 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - November 20, 2020 Category: Pediatrics Source Type: news